Clinical Trial Update: Combination of an Anti-PD1 Antibody With Tisagenlecleucel Reinfusion in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia After Loss of Persistence [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating reinfusion of tisagenlecleucel in combination with an anti-PD1 antibody for children, adolescents, and young adults with r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• B-cell Acute Lymphoblastic Leukemia

Drugs mentioned

• Anti-PD1 antibody
• tisagenlecleucel (tisagenlecleucel)

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: B Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, in Relapse | Phase 1, Phase 2 | Status: RECRUITING